This condition is a common side effect of chemotherapy. Severe myelosuppression, called myeloablation, can be fatal. The body’s bone marrow produces three types of cells: white blood cells, red blood cells, and platelets. Hydroxychloroquine and liver Plaquenil blurry vision reviews Can hydroxychloroquine cause weight gain hair loss Like many other chemotherapy drugs the use of Methotrexate can cause suppression of bone marrow. Although Hydroxychloroquine Watson Laboratories may have an effect on bone marrow that side effect is rare, less than one percent. And although the risk of bone-marrow depression is low. Myelosuppression — also referred to as bone marrow suppression — is a decrease in bone marrow activity resulting in reduced production of blood cells. This condition is a common side effect. Feb 19, 2020 Plaquenil hydroxychloroquine is an antimalarial medication used to treat or prevent malaria, a disease caused by parasites, which enter the body through the bite of a mosquito. Plaquenil is also used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. A decrease in all three types of blood cells is referred to as pancytopenia. It can cause an oxygen shortage and other immune issues. Myelosuppression can decrease some or all of these. Hydroxychloroquine bone marrow suppression Plaquenil and bone marrow. DailyStrength, Myelosuppression Symptoms, Causes, and Treatment Plaquenil mosquito Hydroxychloroquine HCQ is a disease-modifying anti-rheumatic drug DMARD typically used for the treatment of various rheumatic and dermatologic diseases. Three studies of HCQ in OA, including one abstract and one letter, are available and use a wide variety of outcome measures in small patient populations. Hydroxychloroquine in patients with inflammatory and.. Side Effects of Plaquenil Hydroxychloroquine, Warnings, Uses. Hematological Disorders in Patients with Systemic Lupus Erythematosus. Bone Marrow Suppression is a reduction in the activity of the bone marrow, which is the thick liquid inside some of the bones that produces blood cells. The result is a reduction in red blood cells which carry oxygen, white blood cells which fight infection, and/or platelets which control bleeding. Given this presentation, severe bone marrow suppression accompanying pulmonary infection and hemorrhage of the digestive tract associated with MTX and LEF combination therapy was diagnosed. Combination therapy of MTX and LEF was stopped, and celecoxib was also suspended because of possible liver toxicity. Bone marrow suppression is rare, but potentially fatal agranulocytosis or aplastic anaemia can occur. Monitoring the blood count is not generally considered necessary. Much attention has been given to the corneal and retinal damage that may occur following treatment with anti-malarials.